(Q34217829)

31 July 2017

1 reference

title

Recent progress in the pathogenesis and management of essential thrombocythemia (English)

1 reference

31 July 2017

1

Tefferi A

1 reference

31 July 2017

publication date

1 May 2001

1 reference

31 July 2017

1 reference

31 July 2017

volume

25

1 reference

31 July 2017

issue

5

1 reference

31 July 2017

page(s)

369-377

1 reference

The Philadelphia chromosome negative chronic myeloproliferative disorders: a practical overview

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900131-4

7 January 2021

The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukaemia Group

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900131-4

7 January 2021

Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976-1995.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900131-4

7 January 2021

Age and sex distributions of hematological malignancies in the U.K.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900131-4

7 January 2021

Essential thrombocythemia in children

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900131-4

7 January 2021

Clinical course of essential thrombocythemia in 147 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900131-4

7 January 2021

Life expectancy of patients with chronic nonleukemic myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900131-4

7 January 2021

A long-term retrospective study of young women with essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900131-4

7 January 2021

Use of restriction fragment length polymorphisms to determine the clonal origin of human tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900131-4

7 January 2021

Value of Genetic Variants of Glucose-6-Phosphate Dehydrogenase in Tracing the Origin of Malignant Tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900131-4

7 January 2021

A novel clonality assay based on transcriptional analysis of the active X chromosome

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900131-4

7 January 2021

Clonality in myeloproliferative disorders: analysis by means of the polymerase chain reaction

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900131-4

7 January 2021

Evidence for the involvement of B lymphoid cells in polycythemia vera and essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900131-4

7 January 2021

Clonal haemopoiesis in normal elderly women: implications for the myeloproliferative disorders and myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900131-4

7 January 2021

Acquired skewing of X-chromosome inactivation patterns in myeloid cells of the elderly suggests stochastic clonal loss with age.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900131-4

7 January 2021

X chromosome inactivation patterns in normal females

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900131-4

7 January 2021

An X chromosome gene regulates hematopoietic stem cell kinetics

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900131-4

7 January 2021

Monoclonal gammopathies of undetermined significance

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900131-4

7 January 2021

Plasma thrombopoietin levels in thrombocytopenic states: implication for a regulatory role of bone marrow megakaryocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900131-4

7 January 2021

Interaction of thrombopoietin with the platelet c-mpl receptor in plasma: binding, internalization, stability and pharmacokinetics

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900131-4

7 January 2021

Blood thrombopoietin levels in clonal thrombocytosis and reactive thrombocytosis

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900131-4

7 January 2021

Blood thrombopoietin, IL-6 and IL-11 levels in patients with agnogenic myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900131-4

7 January 2021

Plasma thrombopoietin (TPO) levels and expression of TPO receptor on platelets in patients with myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900131-4

7 January 2021

Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900131-4

7 January 2021

Platelet c-mpl expression is dysregulated in patients with essential thrombocythaemia but this is not of diagnostic value

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900131-4

7 January 2021

Marked heterogeneity in protein levels and functional integrity of the thrombopoietin receptor c-mpl in polycythaemia vera

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900131-4

7 January 2021

Strong inverse correlation between serum TPO level and platelet count in essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900131-4

7 January 2021

An activating splice donor mutation in the thrombopoietin gene causes hereditary thrombocythaemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900131-4

7 January 2021

Hereditary thrombocythaemia in a Japanese family is caused by a novel point mutation in the thrombopoietin gene

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900131-4

7 January 2021

The activating splice mutation in intron 3 of the thrombopoietin gene is not found in patients with non-familial essential thrombocythaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900131-4

7 January 2021

Study of the thrombopoitin receptor in essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900131-4

7 January 2021

Endogenous megakaryocyte colonies from peripheral blood in precursor cell cultures of patients with myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900131-4

7 January 2021

Megakaryocyte and erythroid colony formation in essential thrombocythaemia and reactive thrombocytosis: diagnostic value and correlation to complications

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900131-4

7 January 2021

Clonality assays and megakaryocyte culture techniques in essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900131-4

7 January 2021

The determination of spontaneous megakaryocyte colony formation is an unequivocal test for discrimination between essential thrombocythaemia and reactive thrombocytosis

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900131-4

7 January 2021

Spontaneous megakaryocyte colony formation in myeloproliferative disorders is not neutralizable by antibodies against IL3, IL6 and GM-CSF

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900131-4

7 January 2021

Proto-oncogene c-mpl is involved in spontaneous megakaryocytopoiesis in myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900131-4

7 January 2021

A non-peptide compound which can mimic the effect of thrombopoietin via c-Mpl

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900131-4

7 January 2021

Circulating megakaryocyte progenitors in myeloproliferative disorders are hypersensitive to interleukin‐3

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900131-4

7 January 2021

Thrombosis-free survival and life expectancy in 187 consecutive patients with essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900131-4

7 January 2021

Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900131-4

7 January 2021

Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900131-4

7 January 2021

Thrombotic and hemorrhagic complications in essential thrombocythemia. A retrospective study of 103 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900131-4

7 January 2021

Vascular complications of essential thrombocythaemia: a link to cardiovascular risk factors.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900131-4

7 January 2021

Essential thrombocythemias. Clinical evolutionary and biological data

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900131-4

7 January 2021

The incidence of thrombotic and hemorrhagic disorders in association with extreme thrombocytosis: an analysis of 129 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900131-4

7 January 2021

No treatment for low-risk thrombocythaemia: results from a prospective study.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900131-4

7 January 2021

Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900131-4

7 January 2021

The use of aspirin in polycythaemia vera and primary thrombocythaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900131-4

7 January 2021

Outcome analysis of 34 pregnancies in women with essential thrombocythemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900131-4

7 January 2021

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900131-4

7 January 2021

Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900131-4

7 January 2021

Thrombotic complications in essential thrombocythemia with relatively low platelet counts

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900131-4

7 January 2021

Prevention and treatment of thrombotic complications in essential thrombocythaemia: efficacy and safety of aspirin

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900131-4

7 January 2021

Interferon-alpha therapy in polycythemia vera and essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900131-4

7 January 2021

Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900131-4

7 January 2021

Interferon alpha-2b in the long-term treatment of essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900131-4

7 January 2021

Long-term interferon-alpha 2A does not induce sustained hematologic remission in younger patients with essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900131-4

7 January 2021

Primary thrombocythaemia treated with busulphan

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900131-4

7 January 2021

Leukemia and myelodysplasia effect of multiple cytotoxic therapy in essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900131-4

7 January 2021

The treatment of essential thrombocythaemia with radioactive phosphorus

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900131-4

7 January 2021

Outcome of 259 patients with primary proliferative polycythaemia (PPP) and idiopathic thrombocythaemia (IT) treated in a regional nuclear medicine department with phosphorus-32--a 15 year review

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900131-4

7 January 2021

Anagrelide: A New Drug for Treating Thrombocytosis

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900131-4

7 January 2021

Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Anagrelide Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900131-4

7 January 2021

Treatment of essential thrombocythemia with anagrelide.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900131-4

7 January 2021

Treatment of children with anagrelide for thrombocythemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900131-4

7 January 2021

Efficacy, safety and tolerability of anagrelide in the treatment of essential thrombocythaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900131-4

7 January 2021

Anagrelide, a novel platelet lowering option in essential thrombocythaemia: treatment experience in 48 patients in Germany.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900131-4

7 January 2021

Is treatment with hydroxyurea leukemogenic in patients with essential thrombocythemia? An analysis of three new cases of leukaemic transformation and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900131-4

7 January 2021

Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900131-4

7 January 2021

Acute leukaemia after hydroxyurea therapy in polycythaemia vera and allied disorders: prospective study of efficacy and leukaemogenicity with therapeutic implications.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900131-4

7 January 2021

Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900131-4

7 January 2021

Essential thrombocythemia terminating in acute leukemia with minimal myeloid differentiation--a brief review of recent literature

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900131-4

7 January 2021

Acute leukemia as a natural sequel to primary thrombocythemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900131-4

7 January 2021

New drugs in essential thrombocythemia and polycythemia vera

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900131-4

7 January 2021

Markedly Reduced Expression of Platelet c-mpl Receptor in Essential Thrombocythemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900131-4

7 January 2021

Thrombopoietin: the primary regulator of platelet production [see comments]

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900131-4

7 January 2021

10.1016/S0145-2126(00)00131-4

Identifiers

DOI

1 reference

31 July 2017

1 reference